Arrowhead Pharmaceuticals

ARWR · NASDAQ

$58.92+$1.69 (+2.95%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $57.23

Latest news

NewsOct 14, 1:05 PM ETVandana Singh
Arrowhead Pharmaceuticals Advances Alzheimer's Drug Push With Promising Early Clinical Results
Press releaseOct 14, 7:30 AM ETBusiness Wire
Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunteers
Press releaseOct 7, 7:30 AM ETBusiness Wire
Arrowhead Pharmaceuticals Granted Entry in the FDA STAR Pilot Program for Plozasiran in Severe Hypertriglyceridemia
Press releaseSep 29, 7:30 AM ETBusiness Wire
Arrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies
NewsSep 23, 1:08 PM ETPiero Cingari
Nasdaq 100 Slips, 10-Year Yields Hit 19-Year Highs: Stock Market Today
NewsSep 16, 7:39 AM ETVandana Singh
Arrowhead Achieves Clinical Validation for New Drug Platform
NewsSep 15, 1:27 PM ETPiero Cingari
10-Year Yield Tops 5%, Oil Storms Past $105: Stock Market Today
Press releaseSep 15, 7:30 AM ETBusiness Wire
Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
Press releaseSep 3, 7:30 AM ETBusiness Wire
Arrowhead Pharmaceuticals to Participate in Upcoming September 2026 Investor Conferences
Press releaseAug 30, 11:30 AM ETBusiness Wire
Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia
Press releaseAug 24, 7:30 AM ETBusiness Wire
Arrowhead Pharmaceuticals to Present New Clinical Data at the European Society of Cardiology Congress
Press releaseAug 17, 9:33 AM ETBusiness Wire
People Living with Familial Chylomicronaemia Syndrome (FCS) in Germany Have Access to REDEMPLO® (plozasiran) as a New Treatment Option to Reduce Triglycerides
NewsAug 4, 4:02 PM ET
Arrowhead Pharmaceuticals Enters Agreement With Undisclosed Third Party To Acquire An FDA Rare Pediatric Disease Priority Review Voucher For Its Upcoming SNDA Submission For Plozasiran, Anticipated Before The End Of 2026
Press releaseAug 4, 4:01 PM ETBusiness Wire
Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results
Press releaseAug 4, 4:00 PM ETBusiness Wire
Arrowhead Pharmaceuticals Acquires FDA Priority Review Voucher
Press releaseAug 3, 4:30 PM ETBusiness Wire
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
NewsJul 28, 1:35 PM ET
4 Health Care Stocks With Whale Alerts In Today’s Session
Press releaseJul 27, 7:30 AM ETBusiness Wire
Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia
NewsJul 22, 2:25 PM ETVandana Singh
Arrowhead Drug Shows Strong Efficacy In Cutting Blood Fat
NewsJul 22, 12:58 PM ETPiero Cingari
Stock Market Today: Nasdaq 100 Falls as Crude Rallies to $88
NewsJul 22, 12:09 PM ETAvi Kapoor
Crude Oil Gains 2%; GE Vernova Shares Fall After Q2 Earnings
Press releaseJul 22, 7:30 AM ETBusiness Wire
Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia
Press releaseJul 21, 7:30 AM ETBusiness Wire
Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Third Quarter Results
Press releaseJun 22, 12:33 PM ETBusiness Wire
Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
Press releaseJun 18, 7:30 AM ETBusiness Wire
Arrowhead Pharmaceuticals to Host a Webinar on its Cardiometabolic Pipeline as Part I of the 2026 Summer Series of R&D Webinars
Press releaseJun 2, 7:30 AM ETBusiness Wire
Arrowhead Pharmaceuticals to Participate in Upcoming June 2026 Events
Press releaseMay 27, 7:00 AM ETBusiness Wire
Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026
Press releaseMay 26, 10:00 AM ETBusiness Wire
Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS) Congress
Press releaseMay 12, 8:30 AM ETPRNewswire
Wall Street's Cardiac Bet: Where Diagnostics Meet the Money
NewsMay 7, 4:04 PM ET
Arrowhead Pharma Q2 EPS $(0.93) Beats $(1.14) Estimate, Sales $73.737M Miss $79.991M Estimate
Press releaseMay 7, 4:01 PM ETBusiness Wire
Arrowhead Pharmaceuticals Reports Fiscal 2026 Second Quarter Results
Press releaseMay 5, 8:00 AM ETBusiness Wire
Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals
Press releaseMay 4, 7:30 AM ETBusiness Wire
Arrowhead Pharmaceuticals to Participate in Upcoming May 2026 Events
NewsMar 26, 1:47 PM ETVandana Singh
Ionis Pharmaceuticals Repriced Drug Ahead Of Key FDA Decision Signals Push Into Larger Market
NewsMar 25, 2:32 PM ETAvi Kapoor
AAR Foods Posts Upbeat Q3 Earnings, Joins Braze, Arm Holdings And Other Big Stocks Moving Higher On Wednesday
NewsFeb 26, 1:45 PM ETKaustubh Bagalkote
Why Is CRISPR Therapeutics Stock Surging Thursday?
NewsFeb 10, 7:00 AM ET
Breaking Down Arrowhead Pharma: 18 Analysts Share Their Views
NewsFeb 5, 4:08 PM ET
Arrowhead Pharma Q1 Earnings Summary & Key Takeaways
NewsNov 26, 12:16 PM ETAvi Kapoor
Gold Gains Over 1%; Nutanix Shares Fall After Q1 Results
NewsNov 26, 11:30 AM ETAvi Kapoor
Urban Outfitters, Arrowhead Pharmaceuticals, Petco Health and Wellness And Other Big Stocks Moving Higher On Wednesday
NewsJul 23, 11:00 AM ETAvi Kapoor
GE Vernova Posts Better-Than-Expected Earnings, Joins Thermo Fisher Scientific, Lennox International, General Dynamics And Other Big Stocks Moving Higher On Wednesday

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Arrowhead Pharmaceuticals Advances Alzheimer's Drug Push With Promising Early Clinical Results

Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunteers

Arrowhead Pharmaceuticals Granted Entry in the FDA STAR Pilot Program for Plozasiran in Severe Hypertriglyceridemia

Arrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies

Nasdaq 100 Slips, 10-Year Yields Hit 19-Year Highs: Stock Market Today

Arrowhead Achieves Clinical Validation for New Drug Platform

10-Year Yield Tops 5%, Oil Storms Past $105: Stock Market Today

Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

Arrowhead Pharmaceuticals to Participate in Upcoming September 2026 Investor Conferences

Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia

Arrowhead Pharmaceuticals to Present New Clinical Data at the European Society of Cardiology Congress

People Living with Familial Chylomicronaemia Syndrome (FCS) in Germany Have Access to REDEMPLO® (plozasiran) as a New Treatment Option to Reduce Triglycerides

Arrowhead Pharmaceuticals Enters Agreement With Undisclosed Third Party To Acquire An FDA Rare Pediatric Disease Priority Review Voucher For Its Upcoming SNDA Submission For Plozasiran, Anticipated Before The End Of 2026

Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results

Arrowhead Pharmaceuticals Acquires FDA Priority Review Voucher

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

4 Health Care Stocks With Whale Alerts In Today’s Session

Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia

Arrowhead Drug Shows Strong Efficacy In Cutting Blood Fat

Stock Market Today: Nasdaq 100 Falls as Crude Rallies to $88

Crude Oil Gains 2%; GE Vernova Shares Fall After Q2 Earnings

Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia

Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Third Quarter Results

Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

Arrowhead Pharmaceuticals to Host a Webinar on its Cardiometabolic Pipeline as Part I of the 2026 Summer Series of R&D Webinars

Arrowhead Pharmaceuticals to Participate in Upcoming June 2026 Events

Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026

Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS) Congress

Wall Street's Cardiac Bet: Where Diagnostics Meet the Money

Arrowhead Pharma Q2 EPS $(0.93) Beats $(1.14) Estimate, Sales $73.737M Miss $79.991M Estimate

Arrowhead Pharmaceuticals Reports Fiscal 2026 Second Quarter Results

Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals

Arrowhead Pharmaceuticals to Participate in Upcoming May 2026 Events

Ionis Pharmaceuticals Repriced Drug Ahead Of Key FDA Decision Signals Push Into Larger Market

AAR Foods Posts Upbeat Q3 Earnings, Joins Braze, Arm Holdings And Other Big Stocks Moving Higher On Wednesday

Why Is CRISPR Therapeutics Stock Surging Thursday?

Breaking Down Arrowhead Pharma: 18 Analysts Share Their Views

Arrowhead Pharma Q1 Earnings Summary & Key Takeaways

Gold Gains Over 1%; Nutanix Shares Fall After Q1 Results

Urban Outfitters, Arrowhead Pharmaceuticals, Petco Health and Wellness And Other Big Stocks Moving Higher On Wednesday

GE Vernova Posts Better-Than-Expected Earnings, Joins Thermo Fisher Scientific, Lennox International, General Dynamics And Other Big Stocks Moving Higher On Wednesday